Heidi Cuthbert

Mesa Laboratories (NASDAQ:MLAB) reported a sharp increase in profitability for its third fiscal quarter, as strong demand for its biopharmaceutical tools more than offset a collapse in its Chinese diagnostic business.

Pentair (NYSE:PNR) reported fourth-quarter and full-year 2025 results on Tuesday, February 3, 2026, delivering a "beat and raise" performance that secured its place in one of the stock market's most exclusive clubs.

Ingredion (NYSE:INGR) reported record full-year 2025 results on Tuesday, underscoring the resilience of its high-margin specialty ingredients despite operational headwinds in North America.

Vertex Pharmaceuticals (NASDAQ:VRTX) and WuXi Biologics announced a major license and research service agreement on Monday, February 2, 2026, aimed at developing an innovative trispecific T-cell Engager (TCE) for B-cell mediated autoimmune diseases.

Bitcoin could extend its decline toward $56,000 as clear catalysts for a sustained rebound remain elusive, according to Galaxy Digital research head Alex Thorn.

Newly released Epstein files show Jeffrey Epstein received an email in March 2019 highlighting a “massive controversy” surrounding Coinbase and its acquisition of blockchain analytics firm Neutrino.

Law firm Fenwick & West has agreed to settle a lawsuit brought by former users of FTX, who alleged the firm played a key role in the fraud that led to the exchange’s collapse.

The latest US manufacturing data has lifted hopes of a Bitcoin rebound after the ISM Manufacturing PMI hit a 40-month high, beating expectations and signalling renewed economic expansion.

New York prosecutors have raised concerns that the US federal stablecoin law known as the GENIUS Act could weaken fraud enforcement and provide legal cover for stablecoin issuers, according to a report.

Donald Trump’s pledge to turn the United States into the world’s crypto capital is under strain as Bitcoin fell below $75,000, deepening losses across digital asset markets.